Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer

AstraZeneca500 enrolled

Overview

The objectives of this study is to obtain information of Faslodex use in the treatment of breast cancer in the clinical practice in Argentina.

In Argentina, Faslodex is indicated for treating postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer with recurrence during or after adjuvant anti-oestrogen therapy or disease progression during anti-oestrogen treatment. This study will provide information regarding the acceptability and compliance of Argentina patients to Faslodex and will provide information regarding the efficacy of this treatment in local population.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Breast Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer with recurrence during or after adjuvant anti-estrogen therapy or disease progression during anti-estrogen treatment, currently receiving Faslodex * Signature of the informed consent Exclusion Criteria: * Any contraindication to Faslodex administration

Locations (16)

Research Site

Bahía Blanca, Buenos Aires, Argentina

Research Site

Campana, Buenos Aires, Argentina

Research Site

Ciudad de Buenos Aires, Buenos Aires, Argentina

Outcomes

Primary Outcomes

To collect real life data of acceptability and compliance on the use of Faslodex in the Argentine population.

Time frame: monthly

To collect real life data of efficacy on the use of Faslodex in the Argentine population.

Time frame: monthly

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.